Text Size

DNA Methylation and Urothelial Carcinoma

This study is currently recruiting participants.
Verified June 2011 by China Medical University Hospital
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01378052
First received: June 20, 2011
Last updated: June 21, 2011
Last verified: June 2011
History of Changes

June 20, 2011
June 21, 2011
June 2011
June 2012   (final data collection date for primary outcome measure)
urothelial carcinoma [ Time Frame: one year ] [ Designated as safety issue: No ]
Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
Same as current
Complete list of historical versions of study NCT01378052 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
DNA Methylation and Urothelial Carcinoma
Level of DNA Methylation in People With Urothelial Carcinoma

Many studies previously showed the significant association between urinary arsenic profiles and urothelial carcinoma (UC) risk and observed the increased UC risk in people with lower plasma folate and higher homocysteine than those with higher plasma folate and lower homocysteine. The investigators would expect to explore the interactions among global DNA methylation, one-carbon metabolic pathway factors, urinary arsenic profiles and UC.
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

This is a hospital-based case-control study. Patients with urothelial carcinoma are recruited by pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists. Healthy controls without evidence of UC or any other malignancy were recruited including those receiving adult health examinations at China Medical University Hospital.
Urothelial Carcinoma
Not Provided
  • urothelial carcinoma pateints
  • healthy controls
    Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of urothelial carcinoma
  • The voluntary of participating the study

Exclusion Criteria:

  • Age smaller than 20 years
  • Pregnant women
  • Not willing to participate the study because of their personal reasons
Both
21 Years and older
Yes
Contact: Chao-Hsiang Chang, PhD 886-4-22052121 ext 4439 urology8395@yahoo.com.tw
Taiwan
 
NCT01378052
DMR100-IRB-092
Yes
Chao-Hsiang Chang, Department of Urology
China Medical University Hospital
Not Provided
Principal Investigator: Chi-Jung Chung, PhD Department of Health risk Management, China Medical University
China Medical University Hospital
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP